Northern Lipids Inc is pleased to announce the appointment of Dr. Norbert Maurer as Director of R&D
February 10, 2015 – Northern Lipids Inc.
Dr. Maurer comes to NLI with over 20 years of experience in the development of delivery technologies for conventional chemotherapeutic agents and biopharmaceuticals such as therapeutic antibodies and nucleic acid-based drugs. Most recently as head of formulations at CDRD, Dr. Maurer focused on the formulation of drugs, from novel small molecule therapeutics to the new macromolecular therapeutics coming from proteomics and genomics research. Previously, Norbert was involved with a number of Vancouver-based pharmaceutical companies that tended to focus on delivery platforms.
Dr. Maurer obtained his PhD in Physical Chemistry while living in Austria followed by post-doctoral training in the Biochemistry Department (The Liposome Research Unit) of the University of British Columbia. He authored 27 peer-reviewed papers, review articles and book chapters and is named on six patents/patent applications.
About Northern Lipids Inc.
Northern Lipids Inc (NLI) is a Contract Research & Manufacturing Organization (CRMO) that provides services to biotechnology and pharmaceutical companies engaged in the development and manufacture of complex drug delivery systems; including liposomes, emulsions and micelles. The Company has two sites in Burnaby, British Columbia where it operates a state-of-the-art GMP facility for manufacturing sterile products and a well equipped research centre for formulation development and scale up.